Best GLP-1 Programs for Women (2026):
Our Honest Rankings

Women have been the dominant users of GLP-1 medications since 2019, and a 2026 Johns Hopkins Bloomberg School of Public Health meta-analysis of 64 clinical trials confirmed what many clinicians had observed anecdotally: women lose significantly more weight on GLP-1 medications than men — an average of 11% of body weight versus 7% for men. The researchers attribute this to synergistic interactions with estrogen, differences in pharmacokinetics, and women’s lower median body weight. But not all GLP-1 programs are equally well-suited for women, and the right choice depends on your age, hormonal status, and what you are willing to pay. If you want a personalised recommendation, take our free 2-minute quiz here.

What Women Need to Know Before Choosing a Program

GLP-1s Work Better in Women — But Hormonal Status Matters

The Johns Hopkins 2026 meta-analysis found women average 11% body weight loss on GLP-1 medications compared to 7% for men — a statistically significant difference. The researchers attribute this to estrogen’s synergistic interaction with GLP-1 receptors, differences in how women’s bodies metabolise the drug, and lower baseline body weight.

However, hormonal status significantly affects outcomes. A 2025 ENDO conference finding from Mayo Clinic showed that tirzepatide combined with hormone replacement therapy (HRT) produces approximately 35% more weight loss than tirzepatide alone in perimenopausal women. This is because estrogen decline during perimenopause dysregulates the HPA axis, raises baseline cortisol, and drives hormonal belly fat redistribution that makes weight loss harder — and GLP-1 medications work better when the hormonal environment is more favourable.

For women over 40 in perimenopause or menopause, this means the question is not just “which GLP-1 program” but also “should I be discussing HRT with my doctor at the same time?”

Menstrual Cycle Considerations

A 2026 Nature Health analysis of 67,008 users flagged menstrual irregularities as a reported side effect in some women on GLP-1 medications. The mechanism is not fully understood, but rapid weight loss can affect hormonal cycling. Women who are trying to conceive should discuss GLP-1 use with their OB-GYN, as the medications are not recommended during pregnancy.

The BMI Threshold Problem

Most GLP-1 telehealth platforms require a BMI of 27–30 or higher for eligibility. Many perimenopausal women gain weight in the abdomen specifically — a pattern associated with metabolic dysfunction — while maintaining a “normal” BMI of 23–26. Some platforms (notably Mochi Health) accept patients with a BMI as low as 23, which is more appropriate for this population.

Our Rankings: Best GLP-1 Programs for Women in 2026

The Top Picks Explained

Best Overall for Women: Mochi Health

Mochi Health earns the top spot for women for three reasons beyond price. First, their flat-rate pricing ($99/mo semaglutide, $199/mo tirzepatide) means no cost surprises as your dose escalates. Second, they include an insurance concierge — genuinely valuable for women who may have employer coverage that includes GLP-1s. Third, they include a registered dietitian, which matters because women on GLP-1 medications face higher muscle loss risk and benefit from nutritional guidance on protein intake. Their BMI threshold of 23+ also makes them more accessible to perimenopausal women who may not meet the standard 27–30 BMI threshold at other platforms.

Best Women-Branded Platform: Hers

Hers is the women-specific counterpart to Hims, with a clinical team and app experience designed for women. Their most significant 2026 development is a partnership with Novo Nordisk that gives Hers patients access to the FDA-approved oral Wegovy pill at $149/month (introductory rate through August 2026). This is a genuine differentiator — brand-name, FDA-approved, oral, at a competitive price. The mandatory $149/month membership fee raises the true total cost, but for women who specifically want the brand-name drug in pill form, Hers is the most accessible option.

Best for Service Quality: Yucca Health

Yucca Health consistently receives the highest customer service ratings of any platform we have reviewed. Their free UPS 2-Day Air shipping, B12-boosted formulations, and mandatory onboarding call (which many women find reassuring) make them the best choice for patients who value service quality over the lowest possible price. At $146/month on a 6-month plan, they are also genuinely competitive on cost.

Best for Needle-Free Options: SkinnyRx

Many women prefer to avoid self-injection. SkinnyRx offers the widest range of medication formats including oral drops and tablets alongside injectable options. For women who are needle-averse, SkinnyRx is the most format-flexible option in the market.

Best Entry Price: OrderlyMeds

OrderlyMeds’ SimpleStart program at $74/month for semaglutide (3-month introductory rate) is the lowest entry price in the market. Their 22,000-member Facebook community is also particularly active among women, providing peer support that many find valuable during the first months of treatment.

Semaglutide vs Tirzepatide: Which Is Better for Women?

Both medications work well in women, but the data increasingly favours tirzepatide for maximum weight loss. The SURMOUNT-5 head-to-head trial showed tirzepatide produces 20.2% average weight loss versus 13.7% for semaglutide. For women, the dual GIP/GLP-1 mechanism of tirzepatide may be particularly relevant — GIP receptors interact with estrogen signalling in ways that may enhance fat metabolism in women.

The Mayo Clinic ENDO 2025 finding that tirzepatide combined with HRT produces ~35% more weight loss than tirzepatide alone is the most compelling reason for perimenopausal women to consider both tirzepatide and a conversation with their doctor about HRT simultaneously. Our full semaglutide vs tirzepatide comparison covers the clinical evidence in detail.

The Cost Trade-Off

Tirzepatide costs approximately $100/month more than semaglutide across most platforms. Given the significantly greater weight loss, the cost-per-pound-lost calculation often favours tirzepatide for patients who can afford it. For women on a tighter budget, semaglutide at $99/month through Mochi Health remains an excellent and evidence-backed choice.

Affiliate Disclosure: TheDoseReport.com participates in affiliate programs. Some links on this site may earn us a commission at no extra cost to you. This does not influence our editorial content. All reviews and opinions are our own.

Medical Disclaimer: This website does not provide medical advice. All content is for informational purposes only. Always consult a qualified healthcare professional before starting any weight loss program or medication.